Impact of fluctuations in the number of inbound patients on the cell processing business
First written in FY2024. 2 of 5 entries say "Materialised", first in 2026-05-15. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026MaterialisedAnnual report
「The number of Chinese visitors to Japan declined against a backdrop of worsening Japan-China relations and other factors, causing the number of inbound patients to remain sluggish. As a result, the number of cell processing outsourcing projects, primarily for foreign patients, fell significantly short of plan.」
The risk of fluctuations in the number of inbound patients materialized during the year, with the decline in Chinese visitors to Japan and the failure to meet the plan for cell processing outsourcing projects weighing on performance. - FY2025RestatedAnnual report
「Going forward, if the number of visits by inbound patients fluctuates due to the status of COVID-19 infections or other factors, this may affect the performance of the Group.」
Although the number of inbound patients has recovered to a high level, fluctuations in patient visits continue to be identified as a risk to the cell processing business. - FY2024First statedAnnual report
「The spread of COVID-19 caused a sharp decline in inbound patients, resulting in lower revenue from this business and a significant impact on the Group's performance.」
It states that, while risks materialized in the past, the number of outsourced projects increased in the current period as inbound demand recovered.